Aptamers: Two Deals Down, One Big Deal Up

Two aptamer deals died in March--Corgentech's with Bristol after the key project failed in Phase III and Dynavax's with UCB, after the Belgian company re-thought its commitment. Meanwhile, Coley signed a giant alliance with Pfizer, big enough, the biotech hopes, to allow it to go public. But the technology's still too early to justify Pfizer's acquiring Coley the way it's acquired Angiosyn, Idun, and Esperion.